Marx Biotechnology (MBT) develops a blood test to diagnose the early onset of graft-versus-host disease (GVHD) in order to save lives, reduce costs, and improve patient care, allowing doctors to make quick, accurate, and efficient decisions on how best to manage and treat their patients. MBT's blood test will diagnose the early onset of GVHD by monitoring functions on a molecular level that have to change for the disease to occur. The test provides results to physicians within two hours. MBT's big data platform uses a blood test to diagnose numerous diseases, monitor the patient's condition, and indicate what is causing the problem and the best way to treat it.